Overview

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

Eligibility

Inclusion Criteria:

• Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria:

• Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening
• Have a prior or planned surgical treatment for obesity
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity
• Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes
• Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
• Have had within the past 90 days before screening:
  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • hospitalization for unstable angina, or
  • hospitalization due to congestive heart failure
• Have New York Heart Association Functional Classification Class IV congestive heart

  failure

• Have a history of chronic or acute pancreatitis
• Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening